BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26083076)

  • 21. Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy.
    Yang Y; Yang Z; Yang Y
    Front Immunol; 2021; 12():686031. PubMed ID: 34305918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.
    Zhao L; Tong Q; Qian W; Li B; Zhang D; Fu T; Duan S; Zhang X; Zhao J; Dai J; Wang H; Hou S; Guo Y
    Blood; 2013 Dec; 122(26):4230-6. PubMed ID: 24178967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
    Seckinger A; Buatois V; Moine V; Daubeuf B; Richard F; Chatel L; Viandier A; Bosson N; Rousset E; Masternak K; Salgado-Pires S; Batista C; Mougin C; Juan-Bégeot F; Poitevin Y; Hose D
    Front Immunol; 2024; 15():1378813. PubMed ID: 38720892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.
    Ke H; Zhang F; Wang J; Xiong L; An X; Tu X; Chen C; Wang Y; Mao B; Guo S; Ju C; He X; Sun R; Zhang L; O'Connor OA; Li QX
    Sci Rep; 2023 Apr; 13(1):5419. PubMed ID: 37012357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.
    Xiao Z; Chung H; Banan B; Manning PT; Ott KC; Lin S; Capoccia BJ; Subramanian V; Hiebsch RR; Upadhya GA; Mohanakumar T; Frazier WA; Lin Y; Chapman WC
    Cancer Lett; 2015 May; 360(2):302-9. PubMed ID: 25721088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.
    Tuscano JM; Ma Y; Martin SM; Kato J; O'Donnell RT
    Cancer Immunol Immunother; 2011 Jun; 60(6):771-80. PubMed ID: 21347809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
    Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
    Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 33. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
    Buatois V; Johnson Z; Salgado-Pires S; Papaioannou A; Hatterer E; Chauchet X; Richard F; Barba L; Daubeuf B; Cons L; Broyer L; D'Asaro M; Matthes T; LeGallou S; Fest T; Tarte K; Clarke Hinojosa RK; Genescà Ferrer E; Ribera JM; Dey A; Bailey K; Fielding AK; Eissenberg L; Ritchey J; Rettig M; DiPersio JF; Kosco-Vilbois MH; Masternak K; Fischer N; Shang L; Ferlin WG
    Mol Cancer Ther; 2018 Aug; 17(8):1739-1751. PubMed ID: 29743205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
    Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
    Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
    Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index.
    Yang Y; Guo R; Chen Q; Liu Y; Zhang P; Zhang Z; Chen X; Wang T
    Biotechnol Lett; 2018 May; 40(5):789-795. PubMed ID: 29600425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
    Au KM; Tripathy A; Lin CP; Wagner K; Hong S; Wang AZ; Park SI
    ACS Nano; 2018 Feb; 12(2):1544-1563. PubMed ID: 29361211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.